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The recent editorial entitled “Microbiota replacement for 
Clostridium difficile by capsule is as effective as via colonoscopy” 
by Saha & Khanna provides an excellent review of the 
clinical efficacy, as well as the delivery options, for fecal 
microbiota transplantation (FMT) for patients suffering 
from a recurrent, C. difficile infection (rCDI) (1). The review 
also highlights the uncertainty that is relating to the optimal 
dose, or the delivery route for FMT (1). Admittedly, FMT 
is a crude and archaic method, with many drawbacks despite 
the high efficacy and lack of short term safety concerns. 
The long-term consequences remain to be determined, as 
the potentials for transferring infectious agents, or donor 
traits such as obesity, exist. 
The mechanisms behind FMT’s efficacy are largely 
unknown (2), which can prevent the development of a 
targeted, refined microbiome based therapy. The contents 
of FMT are complex, and include both live and dead 
bacteria as well as non-bacterial components such as 
viruses, bile acids and proteins (2). It is not known if some, 
or all of these components are necessary for the clinical 
efficacy of FMT. When considering the gut microbiome, 
it is vital to consider not only the bacteria, but also the 
viruses (virome), the fungal elements (mycobiome) and 
many small molecules, such as bile acids, and short chain 
fatty acids (SCFAs). These factors may be contributing 
to, or perpetuating gut dysbiosis, a hallmark of C. difficile 
pathogenesis.
It is assumed that live bacteria are necessary for FMT to 
work. Bacteriophages, which make up the majority of the 
gut virome, were initially thought to simply have a predator-
prey relationship with microbial populations. However, 
recent research has demonstrated that bacteriophages have 
the ability to influence bacterial cell growth, virulence 
and favorable adaptation to changing environments (3). 
Previous studies have examined the possibility of treating 
CDI with bacteriophages alone. In an in vitro human colon 
organoid model of the CDI, although inoculation with a 
bacteriophage belonging to the abundant Myoviridae family, 
ΦCD27, led to the decrease in C. difficile toxin production, 
it was not sufficient to eradicate the C. difficile (4). It took 
a cocktail of four C. difficile myoviruses to eradicate the C. 
difficile, in a batch fermentation model of CDI (5). This 
study suggests that a combination of bacteriophages may 
be needed to treat CDI, and to maintain the stability of a 
microbial community. 
In human studies, there is evidence that FMT is 
associated with the transfer of not just bacteria, but also 
bacteriophages (6). A recent study by Zhu and colleagues, 
has demonstrated that patients with rCDI had both 
bacterial, and viral dysbiosis, when in comparison with 
the fecal samples from healthy control groups (6). In 
addition, FMT led to changes in both the bacterial and 
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viral composition, whereas rCDI patients treated with 
vancomycin alone, were altered only in their bacterial 
composition (6). In a case report, a patient’s diarrhea 
resolved 2 weeks after FMT but the changes in the fecal 
bacterial composition did not occur until 7 months later (7). 
However, this patient’s virome was similar to the donor 
shortly after FMT (7), suggesting that the viral component 
of the FMT from the donor may be enough to induce 
clinical improvement. Intriguingly, Ott and colleagues used 
fecal filtrate, void of live bacteria, which prevented CDI 
recurrence in 5 patients (8). Through fecal composition 
analysis, again they were able to demonstrate that the 
bacteriophage composition of the recipient closely 
resembled that of the donor (8). These studies highlighted 
the important role that the bacteriophages potentially play 
in FMT.
The mycobiome is an emerging area of interest, as the 
composition and effect of the fungal organisms on intestinal 
diseases is largely unknown. In an ex vivo study in which 
diarrheal fecal samples of patients with CDI and non-CDI 
controls were treated with metronidazole or vancomycin, 
changes were observed in the relative abundances of the 
bacterial and fungal taxa compared with the untreated 
samples (9). Interestingly, the fecal samples treated with 
fidaxomicin, a narrow spectrum antibiotic associated with 
reduced CDI recurrence, had limited changes in the fungal 
taxa, post treatment (9). Although this study is limited 
by its ex vivo design, it highlights how C. difficile-directed 
antibiotics, are associated with distinct forms of dysbiosis 
comprising both bacterial and fungal communities, 
suggesting a trans-kingdom interaction between fungi and 
bacteria which may be important in the pathogenesis of C. 
difficile (9). 
Furthermore, small molecules such as bile acids may also 
play an important role in the therapeutic actions of FMT. 
Pre-FMT fecal samples in patients with rCDI were reported 
to have a disproportionate amount of primary bile acids 
when compared to secondary bile acids, which are produced 
through the metabolism of gut commensal bacteria (2). 
However, the post-FMT samples had demonstrated an 
increase in secondary bile acids, a milieu which is inhibitory 
to C. difficile germination and growth, similar to that of 
the healthy donor profile (2). Thus, normalization of the 
bile acid metabolism is another potential mechanism. 
SCFAs, especially butyrate, are known to have an immune 
modulatory effect. Additionally, they are the preferred energy 
source of colonocytes (2,10). A recent study by Seekatz had 
found a complete recovery of the SCFA profile following 
a successful FMT (10). This further supported the notion, 
that these small molecules in donor stools, may contribute 
synergistically to reshape the gut microbiome (10).
Overall, the human gut is a complicated and integrated 
environment that is influenced by bacteria, viruses, fungal 
organisms, and organic compounds. With the development 
of metagenomics, proteomics, and complex in vitro models 
to mimic the human gut environment, we are just beginning 
to understand the vast intricacy between these components. 
New areas of research are also studying other host factors, 
such as the influence of inflammatory cells in the gut. The 
pathogenesis of C. difficile likely includes a combination 
of some or all the aforementioned components. A greater 
understanding of the true mechanisms of action of FMT 
is vital to the future development of d more targeted and 
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